Choose Your Language

Strategy

Through our Win as One strategy, our two ambitions are to reach one billion more consumers by 2030 and deliver industry-leading shareholder returns. We will deliver these ambitions via four strategic drivers: Health in more hands; Superior brands; Wired for excellence; and Full potential people — underpinned by our Health Inclusivity and Sustainability strategy.

Share


Our purpose to deliver better everyday health with humanity guides us in everything we do. 


To deliver our purpose, we have defined two ambitions, to provide everyone at Haleon with a ‘North Star’ and guide us in everything we do:

1. Reach 1bn more consumers by 2030
We are proud of the impact we have on people around the world. Haleon helps 1.4 billion consumers look after their everyday health, by 2030 and we aim to serve a billion more.

2. Generate industry leading shareholder returns
We will create value for shareholders and generate industry-leading shareholder returns by driving continued top-line growth, capturing significant gross profit margin opportunity, and continuing to transform into a more agile and performance-focused consumer company.

Our Win as One strategy is all about raising the ambition and realising our full potential. It is how we are mobilising and driving the organisation forward, to capture the opportunities we see ahead. To Win as One, we have embedded four behaviours They are not just aspirational – they are actionable, shaping how we prioritise, make decisions, and deliver results.






We will deliver our ambitions through four strategic drivers...


Help many more people solve more of their everyday health needs.

We will achieve this growth by closing the incidence versus treatment gap, bringing advanced benefits by driving innovationled premiumisation driving innovation-led premiumisation, and expanding reach including amongst among lower-income consumers.

Build superior brands – trusted and preferred by consumers, customers and experts.

We do this by developing superior innovation and claims backed by evidence, building trusted relationships to drive engagement and recommendation, having brilliant execution to be first choice at shelf, delighting consumers with pack and sensorial attributes, and building meaningful and different brands.

Create capability advantage across the value chain – powered by data, digital and analytics, and operational excellence.

We are driving efficiency and productivity across the entire value chain. This includes for example reducing unnecessary complexity and inefficiency in our supply chain – radically simplifying our current portfolio and evolving our manufacturing footprint.

Unleash the potential of our people to deliver on our ambitions and cultivating a culture that gives us a genuine competitive advantage.

We are simplifying our processes, uplifting capabiility, driving a culture shift to become a more agile, performance-focused company, streamlining our operating model, and continuing to expand our business services footprint to support our growth and productivity agenda.

To Win as One, we have embedded four behaviours...


Understanding the consumer and putting them at the heart of our decision making.

Building strong relationships and constructively challenging to drive better outcomes.

Effectively using data, with a bias for action, and relentlessly focussing on creating shareholder value.

Consistently stretch and inspire each other to learn and develop.




Our competitive strengths


Consumer first

We focus on understanding the consumer and prioritising solutions that meet their health needs. This helps us to develop fit for purpose innovation and communication, and to enhance our engagement with health professionals who help educate consumers. There is a huge opportunity to create products that improve people’s quality of life, not just treat their health needs.

Trusted science

We leverage the technical and scientific expertise of our scientists, and are investing c. £200m in a new cutting-edge R&D facility. Our regulatory excellence is world class, and we continue to advance this to shape the future of healthcare policy and regulation, innovate with new digital solutions, and actively support product licences. Science is at the heart of our brands, and we are going to continue investing here, but in new digital ways. In addition to our high-quality clinical studies, we are expanding the use of ‘real-world-evidence studies’ to provide robust insight into both usage and quality-of-life benefits of products for our consumers.

Pharmacy channel expertise

Pharmacies are considered a first point of care for consumers. Our geographic footprint and extensive sales force give us strong reach in this channel, where recommendation of trusted health products matters. We have direct relationships with pharmacists, anchored in: offering best-in-class shopper experience through a variety of tools and solutions; leading category growth via our in-store execution programmes; and educating and partnering with pharmacists to best engage with their customers, enriched with digital capabilities.


Investment case

  • Global leader in the c.£200bn consumer healthcare market1 which is underpinned by long term structural tailwinds and resilient categories
  • Portfolio of Superior Brands which are rooted in Trusted Science which outperform through our leading route to market capabilities
  • Significant headroom for growth in addressing incidence vs treatment penetration, innovation led premiumisation and expanding reach to low-income consumers
  • As a standalone company, we are driving a step change in our supply chain which will drive £800m in gross cost savings over the next five years
  • Compelling financial algorithm of 4-6% annual organic revenue growth3 and high-single digit adjusted operating profit3 growth at constant currency enabling strong EPS4 growth
  • Strong free cash generation allowing disciplined capital allocation resulting in industry-leading shareholder returns


1 Nicholas Hall (VMS,OTC) and Global Data (Oral Health) 2024

3 See FY 2024 Annual Report for definitions

4 Refers to adjusted EPS; see FY 2024 Annual report for definitions